Efficacy analysis of sacubitril/valsartan in the prevention and treatment of cardiac dys-function related to tumor therapy
10.12354/j.issn.1000-8179.2024.20240149
- VernacularTitle:沙库巴曲缬沙坦防治肿瘤治疗相关心功能不全的效果分析
- Author:
Lin YITING
1
;
Han QING
;
Guo XIAOBO
;
Zhang HONGMEI
Author Information
1. 空军军医大学基础医学院学员四大队(西安市 710032)
- Keywords:
sacubitril/valsartan;
cancer therapy-related cardiac dysfunction(CTRCD);
heart failure;
tumor cardiology
- From:
Chinese Journal of Clinical Oncology
2024;51(4):186-191
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of sacubitril/valsartan in the treatment of cancer therapy-related cardiac dysfunction(CTRCD).Methods:A comprehensive analysis of all the literature on sacubitril/valsartan therapy for CTRCD published in Pubmed,Web of Science,Cochrane Library,Medline,and Embase from the inception of the database up to March 2023 was conducted,summarizing the tim-ing of drug administration,dosage,and efficacy,and further systematically summarizing the clinical studies on the use of the drug for the prevention of CTRCD.Results:After 3-12 months of treatment with sacubitril/valsartan for CTRCD,NYHA in cancer patients improved from grade Ⅱ-Ⅳ to grade Ⅰ-Ⅱ,LVEF increased by 3.0%to 37.0%,and NT-proBNP decreased by 280.0-65 498.0 pg/mL.Conclusions:The sacu-bitril/valsartan demonstrates efficacy in managing CTRCD and holds significant clinical utility in enhancing LVEF,GLS,and other patient indic-ators,thereby enabling the continuation of anti-tumor therapy and prolonging survival for cancer patients.
